1 completed, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow SAR425899: new trials by email Literature Review of SAR425899 trials Research Report on SAR425899
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease SAR425899, Placebo - Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus | Phase 2 | Withdrawn | Sanofi | 2019-05-23 | 2022-04-13 | |
| A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus SAR425899, Placebo, Liraglutide - Type 2 Diabetes Mellitus | Phase 2 | Completed | Sanofi | 296 | 2016-12-02 | 2022-03-24 |
Diabetes Mellitus, Type 2 (2) · Non-alcoholic Fatty Liver Disease (1)
Sanofi (2)
Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Mexico (1) · Russia (1) · Spain (1) · United States (1)
2016 (1), 2017 (1)